Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Transcatheter aortic valve implantation with the self-expanding Portico valve system in an all-comers population: procedural and clinical outcomes

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Mechanical circulatory support for decompensated heart failure: the last remaining indication for intra-aortic balloon pump?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Transcatheter mitral valve repair: a step back from the edge

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Percutaneous coronary and structural interventions in women: a position statement from the EAPCI Women Committee

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The invisible army of women in interventional cardiology: EAPCI Women mission to make them visible

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIMS: Transcatheter aortic valve implantation (TAVI) is an established therapy for patients with severe aortic stenosis (AS). The aim of this study was to evaluate the newer-generation Portico TAVI system in an all-comers population.

METHODS AND RESULTS: This single-centre study included 216 patients with severe AS (Society of Thoracic Surgeons [STS] score 4.3±3.0%). The Portico valve was implanted using the transfemoral (91.2%), transsubclavian (5.6%) and transcaval (3.2%) access. Device success was achieved in 94.4% of cases. At 30 days, mortality and stroke rates were 2.3% and 0.5%, respectively. Early safety was achieved in 91.7% of cases. More-than-mild paravalvular leak (PVL), as assessed by echocardiogram, was observed in 3.4% of the patients, with rates of 4.9% and 1.9% in the first and second half of the cohort, respectively. A permanent pacemaker was implanted in 15.8% of those without prior pacemaker, with a rate of 11.1% in the second half of the cohort. At one year, incidence rates for all-cause mortality and stroke were 12.3% and 2.3%, respectively. In the low-risk group (STS <4%; n=128), Kaplan-Meier estimates at 30 days and one year were 0% and 7.5% for all-cause mortality and 0.8% and 2.2% for stroke, respectively. Haemodynamic improvements persisted over time with a mean transvalvular gradient of 7.0±3.0 mmHg at one-year follow-up.

CONCLUSIONS: The Portico TAVI system was safe to implant and achieved a high device success rate. With learning curve effects, the device achieves lower rates of PVL and pacemaker implantation and provides adequate clinical and haemodynamic outcomes up to one year.

Original languageEnglish
JournalEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Issue number6
Pages (from-to)621-628
Number of pages8
Publication statusPublished - 20 Aug 2018

ID: 56380079